Close Menu

More articles about Cancer

The model could shift which patients receive gene expression profiling assays but might not change the number of tests ordered.

The study showed an overall benefit regardless of BRCA mutation or HRD status, but some analysts believe the FDA still might require a CDx for niraparib. 

Although Tesaro used Myriad's BRCA and HRD tests to stratify patients, in the NOVA trial all recurrent ovarian cancer patients benefitted from niraparib. 

Scientists at Memorial Sloan Kettering Cancer Center, led by Gabriela Chiosis, revealed how the complexes are important for tumor survival in certain cases.

Experts at CAP16 said most practicing pathologists operate within specialties and rarely cross the divide into other test disciplines, which thwarts optimal patient care.

The project team is driving the development of practice guidelines because sample handling and quality are often not up to the mark.    

The Xpert Bladder Cancer Monitor test for the GeneXpert system has a high negative predictive value and provides results non-invasively in about 90 minutes.

The positive insurance coverage decision for ConfirmMDx is one of several the company has received in recent months.

The state has given its approval for the company to market its ThyGenX next-generation sequencing oncogene panel for indeterminate thyroid nodules.

Cambridge Bioscience will exclusively distribute the Xcell platform in the UK and BioStream will disburse the system in Japan.

The investment bank said NeoGenomics and its clients are likely to benefit from a product portfolio expanded by the acquisition of Clarient.

The partners will provide testing through a program through which they also plan to establish a database of genetic test results and patient outcomes.

The bill comes amid questions about the efficacy of Epigenomics' Epi proColon, the only blood-based cancer screening test approved in the US.

Rosetta's test is designed to analyze the expression of microRNA biomarkers in indeterminate thyroid fine needle aspirate smears to differentiate benign thyroid nodules from malignant ones.

The test can now be used to detect EGFR mutations in tissue and blood for lung cancer patients considering treatment with the tyrosine kinase inhibiting drugs Tarceva and Tagrisso. 

China-based Burning Rock will develop cancer diagnostics for Chinese patients based on the Agilent SureSelect target enrichment system.

In a final policy on comprehensive genomic profiling, Palmetto said that approved registries will have to commit to sharing data, among other requirements. 

The companies will work together to advance the use of ApoCell's rare cell isolation platform for cancer molecular profiling and monitoring in clinical trials.

Some six months after establishing itself as an independent entity, the company plans to roughly double its protein biomarker libraries by the end of the year.

GeneNews' early patient risk stratification tests for colorectal, lung, and prostate cancers will be offered to patients at NueHealth's provider-owned care centers.

Pages